Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

14.95 +0.85 (+6.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Xencor Reports First Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million. 
Via Benzinga
Xencor: Q4 Earnings Insights
Xencor (NASDAQ:XNCR) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor... 
Via Benzinga
Xencor's Earnings Outlook
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Xencor will report... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
From Xencor, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
On Monday, 466 companies hit new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
From Xencor, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan... 
Via Benzinga
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
From Xencor, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
From Xencor, Inc.
Via Business Wire
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
From Xencor, Inc.
Via Business Wire
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
From Xencor, Inc.
Via Business Wire
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine
Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's... 
Via Benzinga
Topics Lawsuit
Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma
Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a... 
Via Benzinga
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
From Xencor, Inc.
Via Business Wire
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Novartis Dumps Another Bispecific Candidate From Xencor Deal
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The... 
Via Benzinga
Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript
XNCR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.